(Q36161207)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15952906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

review article

1 reference

title

Interferon alpha for the treatment of advanced renal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15952906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15952906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Marie-Sarah Dilhuydy

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15952906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15952906%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15952906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15952906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15952906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

749-762

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15952906%20AND%20SRC:MED&resulttype=core&format=json

Present achievements in the medical treatment of metastatic renal cell carcinoma.

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Natural killer cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

IFNalpha regulates NK cell cytotoxicity through STAT1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Recombinant interferon alpha can induce rearrangement of T-cell antigen receptor alpha-chain genes and maturation to cytotoxicity in T-lymphocyte clones in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Renal cell carcinoma: resection of solitary and multiple metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

Interferon alpha /beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.749

21 January 2018

Identifiers

DOI

10.1517/14712598.5.6.749

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15952906%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference